Physician profile
Stephen Daroy
NPI 1740905652
$5,545.02
in general payments reported to CMS, 2019-2025
19 companies · $3,754 in 2025
The $3,754 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $144 · 2024: $1,647 · 2025: $3,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,434 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,433.53 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,092.87 | 2024-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $996.35 | 2023-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $801.60 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $660.95 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $389.94 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $371.98 | 2024-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $305.71 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $254.31 | 2024-2025 | Ingrezza |
| Lundbeck LLC | $108.37 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Bausch Health US, LLC | $103.96 | 2025 | Aplenzin |
| Vanda Pharmaceuticals INC. | $97.23 | 2024-2025 | Fanapt |
| Axsome Therapeutics, INC. | $79.26 | 2024-2025 | Auvelity |
| Neos Therapeutics, LP | $78.12 | 2024-2025 | Adzenys Xr-Odt |
| Corium, LLC | $55.16 | 2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $54.35 | 2024-2025 | Trintellix |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $49.08 | 2024-2025 | Sublocade, Perseris |
| Braeburn INC. | $16.84 | 2024 | Brixadi |
| Validus Pharmaceuticals LLC | $15.12 | 2025 | Raldesy |
| Almatica Pharma LLC | $13.82 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Daroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.